Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease (Q38545359)

4 September 2017

1 reference

title

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease (English)

1 reference

4 September 2017

1 reference

Stanley Fahn

1 reference

4 September 2017

Daphne Robakis

1 reference

4 September 2017

publication date

12 July 2015

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

433-441

1 reference

Epidemiology of Parkinson's disease

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Some observations upon a new inhibitor of monoamine oxidase in brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Medical treatment of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

The medical treatment of Parkinson disease from James Parkinson to George Cotzias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A brief history of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l-DOPA and Carbidopa Chronically

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Does levodopa accelerate the pathologic process in Parkinson disease brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Safinamide: from molecular targets to a new anti-Parkinson drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Medical management of Parkinson's disease: focus on neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Perspectives on MAO-B in aging and neurological disease: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Safinamide for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Pharmacology of selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Selegiline as initial treatment in de novo parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Selegiline's neuroprotective capacity revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Fatigue in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Prevalence of fatigue in Parkinson disease and its clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Excitatory amino acids as a final common pathway for neurologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Dopamine protects neurons against glutamate-induced excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Freezing of gait: moving forward on a mysterious clinical phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Rasagiline in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Selegiline and rasagiline: twins or distant cousins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0249-8

Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease

21 January 2018

1 reference

12 December 2020

Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial

1 reference

12 December 2020

Selegiline slows the progression of the symptoms of Parkinson disease

1 reference

12 December 2020

Molecular neuroanatomy of MAO-A and MAO-B.

1 reference

12 December 2020

Levodopa-induced dyskinesias

1 reference

12 December 2020

SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa

1 reference

12 December 2020

A systematic review of prevalence studies of depression in Parkinson's disease

1 reference

12 December 2020

Some puzzling pharmacological effects of monoamine oxidase inhibitors

1 reference

12 December 2020

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

12 December 2020

Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome

1 reference

12 December 2020

1 reference

12 December 2020

Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat

1 reference

12 December 2020

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

1 reference

12 December 2020

Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease

1 reference

12 December 2020

A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor

1 reference

12 December 2020

Neuroprotection in Parkinson's disease: clinical trials

1 reference

12 December 2020

Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

1 reference

12 December 2020

Recognition and treatment of depression in Parkinson's disease

1 reference

12 December 2020

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

1 reference

12 December 2020

10.1007/S40263-015-0249-8

Identifiers

DOI

1 reference

4 September 2017

1 reference